D. Chen

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

A. Drilon, G. Demetri, M. Ahn, 2021, ESMO Open.

Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex)

M. Chren, S. Fosko, R. Crosby, 2015, The British journal of dermatology.